Results of Operations and Financial Condition. On August 14, 2026, Galectin Therapeutics Inc. (“Galectin Therapeutics”) issued a press release announcing its results of operations and financial condition as of and for the six months ended June 30, 2026, and provided a business update. Galectin hereby incorporates by reference herein the information set forth in its press release dated August 14, 2026 (the “Press Release”), a copy of which is attached hereto as Exhibit 99.1. Except for the his…

Unregistered Sales of Equity Securities.. On July 31, 2026, Galectin Therapeutics Inc. (the "Company") issued 34,376,167 shares of its common stock, par value $0.001 per share (the "Common Stock"), to Richard E. Uihlein, the Company’s Chairman of the Board and largest stockholder, upon the conversion of all outstanding convertible promissory notes (the "Notes") issued to Mr. Uihlein under the following line of credit facilities: (i) the Line of Credit Letter Agreement dated July 25, 2022 (pro…

Results of Operations and Financial Condition. On May 15, 2026, Galectin Therapeutics Inc. (“Galectin Therapeutics”) issued a press release announcing its results of operations and financial condition as of and for the three months ended March 31, 2026, and provided a business update. Galectin hereby incorporates by reference herein the information set forth in its press release dated May 15, 2026 (the “Press Release”), a copy of which is attached hereto as Exhibit 99.1. Except for the histor…

Results of Operations and Financial Condition. On March 31, 2026, Galectin Therapeutics Inc. (“Galectin Therapeutics”) issued a press release announcing its results of operations and financial condition as of and for the year ended December 31, 2025, and provided a business update. Galectin hereby incorporates by reference herein the information set forth in its press release dated March 31, 2026 (the “Press Release”), a copy of which is attached hereto as Exhibit 99.1. Except for the histori…

Director — Dr. Henry Brem: Dr. Henry Brem was appointed as a new member of the Board of Directors.

The filing details retention bonuses for the Chief Medical Officer and Chief Financial Officer.

Director — Marc Rubin: Mr. Rubin resigned from the Board of Directors without any disagreement with the Company.

Entry into a Material Definitive Agreement. On December 19, 2025, Galectin Therapeutics Inc. (the “Company”) and Richard E. Uihlein (the “Lender”) entered into a Line of Credit Letter Agreement (the “December 2025 Supplemental Line of Credit Agreement”), pursuant to which the Lender shall provide the Company a line of credit of up to $10.00 million (the “Line of Credit”) to finance the Company’s working capital needs. The Company may draw upon the Line of Credit through January 31, 2027. Each…

Results of Operations and Financial Condition. On November 14, 2025, Galectin Therapeutics Inc. (“Galectin Therapeutics”) issued a press release announcing its results of operations and financial condition as of and for the nine months ended September 30, 2025, and provided a business update. Galectin hereby incorporates by reference herein the information set forth in its press release dated November 14, 2025 (the “Press Release”), a copy of which is attached hereto as Exhibit 99.1. Except f…

Results of Operations and Financial Condition. On August 14, 2025, Galectin Therapeutics Inc. (“Galectin Therapeutics”) issued a press release announcing its results of operations and financial condition as of and for the six months ended June 30, 2025, and provided a business update. Galectin hereby incorporates by reference herein the information set forth in its press release dated August 14, 2025 (the “Press Release”), a copy of which is attached hereto as Exhibit 99.1. Except for the his…

Entry into a Material Definitive Agreement. On July 8, 2025, Galectin Therapeutics Inc. (the “Company”) and Richard E. Uihlein (the “Lender”) entered into a Line of Credit Letter Agreement (the “July 2025 Supplemental Line of Credit Agreement”), pursuant to which the Lender shall provide the Company a line of credit of up to $10.00 million (the “Line of Credit”) to finance the Company’s working capital needs. The Company may draw upon the Line of Credit through April 30, 2026. Each advance ma…

The filing describes compensation strategies and retention bonuses, not a management change.

Results of Operations and Financial Condition. On May 15, 2025, Galectin Therapeutics Inc. (“Galectin Therapeutics”) issued a press release announcing its results of operations and financial condition as of and for the three months ended March 31, 2025 and provided a business update. Galectin hereby incorporates by reference herein the information set forth in its press release dated May 15, 2025 (the “Press Release”), a copy of which is attached hereto as Exhibit 99.1. Except for the histori…

Results of Operations and Financial Condition. On March 31, 2025, Galectin Therapeutics Inc. (“Galectin Therapeutics”) issued a press release announcing its results of operations and financial condition as of and for the year ended December 31, 2024 and provided a business update. Galectin hereby incorporates by reference herein the information set forth in its press release dated March 31, 2025 (the “Press Release”), a copy of which is attached hereto as Exhibit 99.1. Except for the historic…

Results of Operations and Financial Condition. On November 14, 2024, Galectin Therapeutics Inc. (“Galectin Therapeutics”) issued a press release announcing its results of operations and financial condition as of and for the three months ended September 30, 2024 and provided a business update. Galectin hereby incorporates by reference herein the information set forth in its press release dated November 14, 2024 (the “Press Release”), a copy of which is attached hereto as Exhibit 99.1. Except f…

Results of Operations and Financial Condition. On August 13, 2024, Galectin Therapeutics Inc. (“Galectin Therapeutics”) issued a press release announcing its results of operations and financial condition as of and for the three months ended June 30, 2024 and provided a business update. Galectin hereby incorporates by reference herein the information set forth in its press release dated August 13, 2024 (the “Press Release”), a copy of which is attached hereto as Exhibit 99.1. Except for the hi…

Chief Medical Officer — Dr. Khurram Jamil: Dr. Jamil was promoted to Chief Medical Officer, succeeding Dr. Pol Boudes.

Results of Operations and Financial Condition. On May 15, 2024, Galectin Therapeutics Inc. (“Galectin Therapeutics”) issued a press release announcing its results of operations and financial condition as of and for the three months ended March 31, 2024 and provided a business update. Galectin hereby incorporates by reference herein the information set forth in its press release dated May 15, 2024 (the “Press Release”), a copy of which is attached hereto as Exhibit 99.1. Except for the histori…

Results of Operations and Financial Condition. On March 29, 2024, Galectin Therapeutics Inc. (“Galectin Therapeutics”) issued a press release announcing its results of operations and financial condition as of and for the year ended December 31, 2023 and provided a business update. Galectin hereby incorporates by reference herein the information set forth in its press release dated March 29, 2024 (the “Press Release”), a copy of which is attached hereto as Exhibit 99.1. Except for the historic…

Results of Operations and Financial Condition. On November 13 , 2023, Galectin Therapeutics Inc. (“Galectin Therapeutics”) issued a press release announcing its results of operations and financial condition as of and for the three and nine months ended September 30, 2023 and provided a business update. Galectin hereby incorporates by reference herein the information set forth in its press release dated November 13, 2023 (the “Press Release”), a copy of which is attached hereto as Exhibit 99.1…

Results of Operations and Financial Condition. On November 13 , 2023, Galectin Therapeutics Inc. (“Galectin Therapeutics”) issued a press release announcing its results of operations and financial condition as of and for the three and nine months ended September 30, 2023 and provided a business update. Galectin hereby incorporates by reference herein the information set forth in its press release dated November 13, 2023 (the “Press Release”), a copy of which is attached hereto as Exhibit 99.1…

Results of Operations and Financial Condition. On August 14, 2023, Galectin Therapeutics Inc. (“Galectin Therapeutics”) issued a press release announcing its results of operations and financial condition as of and for the three and six months ended June 30, 2023 and provided a business update. Galectin hereby incorporates by reference herein the information set forth in its press release dated August 14, 2023 (the “Press Release”), a copy of which is attached hereto as Exhibit 99.1. Except fo…

Results of Operations and Financial Condition. On May 15, 2023, Galectin Therapeutics Inc. (“Galectin Therapeutics”) issued a press release announcing its results of operations and financial condition as of and for the year ended December 31, 2022 and provided a business update. Galectin hereby incorporates by reference herein the information set forth in its press release dated May 15, 2023 (the “Press Release”), a copy of which is attached hereto as Exhibit 99.1. Except for the historical i…

Results of Operations and Financial Condition. On March 30, 3023, Galectin Therapeutics Inc. (“Galectin Therapeutics”) issued a press release announcing its results of operations and financial condition as of and for the year ended December 31, 2022 and provided a business update. Galectin hereby incorporates by reference herein the information set forth in its press release dated March 30, 2023 (the “Press Release”), a copy of which is attached hereto as Exhibit 99.1. Except for the historic…